All In Biotech

Drug Trial Radar · NCT03486561

Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine)

Last checked: Nov 20, 2026Latest source record: Apr 3, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

2,000

Planned (sponsor's estimate)

Start

Apr 1, 2018

Primary completion

Sep 30, 2018

Study completion Oct 31, 2018

Sponsor

Lead sponsor
OBS PakistanIndustry
Sponsor type
Industry
First posted
Apr 3, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The rationale of MIDA trial is to determine efficacy and tolerability of ranolazine molecule among Pakistan population and obtain firsthand knowledge about the molecule ranolazine.

Conditions

  • Chronic Stable Angina

Interventions

  • RanolazineDrug

    Ranolazine inhibits sodium and potassium ion channel currents. Inhibition of the late phase of the inward sodium current during cardiac repolarization has been well studied4. In disease states, enhanced sodium-calcium exchange due to augmented late phase of the inward sodium current activity leads to increased cytosolic calcium concentration. Intracellular calcium overload is believed to be critical to the mechanism of decreased left ventricular relaxation caused by ischemia and reperfusion. Elevated left ventricular diastolic wall tension compromises myocardial blood flow even further.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy: Reduction in frequency of Angina with RanolazineTime frame: 24 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.